Introduction
The simple coordination compound, cis-diamminedichloroplatinum(II) or cisplatin, is an effective anticancer drug that has been used in the clinic since 1978. 1 Its success has given rise to the second-generation platinum drugs, carboplatin and oxaliplatin. These three platinum (II) complexes are believed to operate by a similar mechanism. Aquation of the leaving groups, chloride for cisplatin, carboxylate and oxalate for carboplatin and oxaliplatin, respectively, generates reactive cis-diam(m)ineplatinum cations, which react readily with the purine nucleobases in DNA. 2, 3 Structural distortions in DNA induced by platinum binding [4] [5] [6] [7] trigger multiple cellular responses that ultimately lead to cell death. 8, 9 Despite the clinical success of these compounds, the requirement for intravenous administration and associated long-term toxic side effects [10] [11] [12] diminish the quality of life for patients. Platinum anticancer complexes in the +4 oxidation state have shown considerable promise for both oral administration and for reducing systematic toxicity. [13] [14] [15] The orally administered platinum(IV) complex, satraplatin, progressed as far as Phase III in clinical trials. 16 The increased stability of these complexes, due to their low-spin d 6 electronic configuration, aids in their survival of the acidic environment of the stomach before being absorbed into the bloodstream. They operate by a mechanism similar to that of the first and second generation operate by a mechanism similar to that of the first and second generation platinum(II) analogues.
An activation step, namely reduction from Pt(IV) to Pt(II), must occur before aquation and DNA binding, however (Scheme 1).
Scheme 1.
In addition to their kinetic stability, another favorable property of platinum(IV) complexes relative to their platinum(II) counterparts is the presence of two additional coordination sites that can be modified to alter their pharmokinetic properties. By varying the two axial ligands, one can predictably alter the redox potential [17] [18] [19] and lipophilicity [20] [21] [22] of the platinum(IV) complex while leaving the DNA binding cis-diammineplatinum moiety unaltered. Furthermore, the axial coordination sites can serve as binding sites for other biologically active ligands, which may have synergistic effects with platinum therapy, as demonstrated by us [23] [24] [25] and by others. 26, 27 The ability to tether platinum(IV) complexes via the axial ligands to various nano-delivery devices for increased cellular uptake and selectivity [28] [29] [30] [31] [32] [33] [34] [35] is another advantage. The design of new platinum(IV) anticancer complexes, however, is limited by the current synthetic methodology. [36] [37] [38] [39] [40] [41] [42] Most of the newly tested platinum(IV) complexes bear either chloro, hydroxo, or carboxylato axial ligands. The development of new synthetic methodologies for accessing the platinum(IV) manifold can expand the range of complexes having novel properties.
The synthesis of platinum(IV) complexes with axial methyl, ethyl, and isopropyl carbamato ligands was described over 10 years ago. 36 Since then, their biological properties have only rarely been explored, 43 and further investigations of the scope of this synthetic methodology have not been pursued. In the present work, we report both a modification and expansion of this approach through the synthesis of eight new platinum(IV) complexes of both alkyl and aryl carbamates as well as a brief investigation of their biological activity. Computational DFT studies were undertaken to gain a deeper understanding of the electronic structure of these new complexes. The results presented here indicate that platinum(IV) carbamates are a promising new class of potential anticancer agents.
Experimental
General Considerations. All reactions were carried out under normal atmospheric conditions.
Solvents were used as received without additional drying or purification. All isocyanates were used as received from commercial vendors. Bruker APEX CCD X-ray diffractometer with graphite-monochromated Mo-Kα radiation (λ = 0.71073 Å) controlled by the APEX2 software package. 46 Absorption corrections were applied using SADABS. 47 The structures were solved using direct methods and refined on F 2 with the SHELXTL-97 software package. 48, 49 Structures were checked for higher symmetry using PLA-TON. 50 All non-hydrogen atoms were located and refined anisotropically. Unless otherwise stated, hydrogen atoms were placed in idealized locations and given isotropic thermal parameters equivalent to either 1.5 (terminal CH 3 or NH 3 hydrogen atoms) or 1.2 times the thermal parameter of the atom to which they were attached. Structure refinement was carried out using established strategies. 51 Specific details regarding crystal growth and refinement are described in the Supporting Information (SI), and parameters are shown in Tables 1, 2 , and S1. Selected bond lengths and angles for 2 are listed in Table S2 .
Theoretical Calculations. DFT calculations were performed using the Gaussian 03 (Rev.D01) software package. 52 Geometry optimizations, frequency calculations, and molecular orbital generations were all carried out using the B3LYP functional. 53, 54 For the light atoms (carbon, hydrogen, chlorine, nitrogen, oxygen, and fluorine), the 6-31++G(d,p) basis set 55 was used, and for platinum, the LANL2DZ basis set and effective core potential 56 was used. No solvation models were employed; the results described for all complexes are in the gas phase. 
where n is the number of data and p is the number of refined parameters. 
Results and

Scheme 2.
The platinum(IV) carbamates are either white (4 -6) or pale yellow to pale orange (7 - Characterization of compounds 4 -11 was accomplished by NMR spectroscopy, IR spectroscopy, mass spectrometry, elemental analysis, and X-ray crystallography (vide infra). 58, 59 and are close to related platinum(IV) alkyl and aryl carboxylate complexes, which fall between 1000 and 1300 ppm. Although both As shown in Chart 1, three possible conformational isomers exist for the complexes depending on the orientation of substituents about the C-N bond of the carbamate ligand. It is not clear why only two of these isomers are observed by 195 Pt NMR spectroscopy, but it is possible that two of the isomers have very similar chemical shifts and are therefore not resolved as distinct peaks. Another possibility is that one of the conformational isomers is significantly less stable than the other two and never accumulates in a high enough concentration to be observed under equilibrium conditions. The use of variable-temperature 195 Pt NMR spectroscopy to distinguish between chemically similar stereoisomers has been reported before. [61] [62] [63] [64] Our findings here similarly validate this method as a valuable tool for distinguishing isomers that could not otherwise be discerned by the more commonly used 1 H and 13 C NMR spectroscopy.
Chart 1.
X-ray Crystal Structures. Complexes 4 -11 were all characterized by X-ray crystallography and are the first such structurally characterized platinum carbamate complexes. Compound 2 was also crystallographically characterized. Information about this structure and the crystal growth conditions for 2 can be found in the Supporting Information ( Figure S2 , Tables S1 and S2 ).
Relevant bond distances and angles for the platinum carbamate complexes are listed in Table 4 Cyclic Voltammetry. The biological activity of platinum(IV) complexes is mediated by their redox chemistry. In most cases, platinum(IV) complexes, unlike their platinum(II) progeny, do not bind directly to DNA or other biological nucleophiles. 65 The redox potential of platinum(IV) complexes is therefore believed to be an important factor in their efficacy as antitumor agents.
With this possibility in mind, we studied redox potentials of 1 -11 by cyclic voltammetry. to -1.2 V vs. Ag/AgCl. The peak potentials (E p ) for these processes obtained at a scan rate of 100 mV/s are reported in Table 5 and the corresponding cyclic voltammograms are shown in Figure   5 . For a given set of equatorial ligands on a platinum(IV) center, the reduction potential in water predictably changes as the axial ligands are varied. 18, 66 Trifluoracetate ligands produce the most easily reduced (highest redox potential) platinum(IV) complexes, followed by chloride ligands, and then acetate ligands in that order. Axial hydroxo ligands, although not investigated here, give rise to platinum(IV) complexes that are even more difficult to reduce than those with acetate ligands. For example, the precursor complex c,c,t-[Pt(NH 3 ) 2 Cl 2 (OH) 2 ] is reported to have a very negative peak potential at -880 mV in aqueous media. 66 In moving from water to DMF, we find here that this general trend still exists for the chloride and carboxylate ligands, as E p (2) > E p (3) > E p (1). The peak potentials themselves, however, are shifted significantly from those measured in water. In water, the measured peak potentials of 1 and 3 have been determined by others to be -635 and -260 mV, respectively, 66 and the peak potential of 8 was measured to be 5 mV ( Figure S3 ). In DMF, these potentials are -722 (1), -345 (2), and -454 (3) The gas-phase adiabatic electron affinities of 1, 2, and 4 -11 were computed by optimizing the geometry of the 1-electron reduced Pt(III) species as a doublet anion, and then subtracting its total energy from the neutral Pt(IV) species. The results are summarized subtracting its total energy from the neutral Pt(IV) species. The results are summarized in Table 6 . The optimized geometries of the Pt(III) species give rise to stationary points on the potential energy surface, as evidenced by the lack of imaginary frequencies except in the case of 3. A comparison of geometrical parameters of the calculated Pt(IV) and Pt(III) structures is presented in Table 6 . Upon reduction to Pt(III), two mutually trans bond are elongated significantly whereas the other bonds are only altered slightly. This result is expected, for the addition of another electron to the closed-shell Pt(IV) species would require population of an antibonding orbital. For most cases, the axial platinum-carbamate bond is lengthened by approximately 0.4 Å in the Pt(III) complex, which is consistent with the conventional view of Pt(IV) reduction de-picted in Scheme 1. For 6 -8, however, significant bond elongation occurs for the equatorial, mutually trans platinum-chloride and platinum-ammine bonds. These bonds are elongated by approximately 0.34 Å. This result suggests that in some cases elimination of the equatorial ligands may be a viable reductive pathway of platinum(IV) and is consistent with experimental observation of this pathway by others. [67] [68] [69] The computed gas phase adiabatic electron affinities correlate well with the observed peak potentials for reduction. In Figure 8 , the peak potentials are plotted as a function of the electron affinity. The relationship is roughly linear (R 2 = 0.887) and, as expected, larger electron affinities correlate with more positive peak potentials. Table 7 , and dose-response curves can be found in Figures S4 and S5 . In 50 values, the concentrations of platinum where cell growth is inhibited by 50% compared to controls run in the absence of added complexes, measured by the MTT assay following a 72-h exposure. Values are the average of at least three independent experiments, and the reported errors are the corresponding standard deviations.
Conclusions
The synthesis of eight new platinum(IV) carbamate complexes is described. The general reactivity of both aryl and alkyl isocyanates with the important platinum(IV) synthon, c,c,t- Supporting Information Available: X-ray crystallographic data in CIF format, crystal growth and refinement details, crystallographic data collection and refinement parameters for 2 (Table   S1 ), selected interatomic distances and angles for 2 (Table S2) , XYZ coordinates, energies, and lowest frequencies for all geometry optimized compounds (Tables S3 -S23) , VT-NMR spectra of 6 ( Figure S1 ), ORTEP diagram of 2 ( Figure S2 ), cyclic voltammogram of 2 in water ( Figure   S3 ), and dose-response curves for A549 ( Figure S4 ) and MRC-5 cells ( Figure S5 ). This material is available free of charge via the Internet at http://pubs.acs.org.
